Clinical Trial: Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07734753) titled 'Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events' on July 24.

Brief Summary: To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.

Study Start Date: July 15, 2025

Study Type: OBSERVATIONAL

Condition: Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events

Intervention:...